Income Taxes	9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes The Company recorded income tax expense of $0.1 million and $0.2 million for the three and nine months ended September 30, 2018, respectively, primarily related to the operating income of the Company’s Cerus Europe B.V. subsidiary. The Company recorded income tax expense of $0.1 million for the three months ended September 30, 2017, primarily for the earnings of its European subsidiary. The Company recorded income tax expense of $4.0 million for the nine months ended September 30, 2017, primarily due to the sale of the Company’s shares of the common stock of Aduro Biotech, Inc. During the three months ended September 30, 2018, the Company completed its review of the amounts provisionally recorded as of December 31, 2017 related to the Tax Cuts and Jobs Act (the “Tax Act”). As a result of this review, there were no adjustments to the provisionally recorded amounts.

Income Taxes

9 Months Ended

Sep. 30, 2018

Note 9. Income Taxes

The Company recorded income tax expense of $0.1 million and $0.2 million for the three and nine months ended September 30, 2018, respectively, primarily related to the operating income of the Company’s Cerus Europe B.V. subsidiary. The Company recorded income tax expense of $0.1 million for the three months ended September 30, 2017, primarily for the earnings of its European subsidiary. The Company recorded income tax expense of $4.0 million for the nine months ended September 30, 2017, primarily due to the sale of the Company’s shares of the common stock of Aduro Biotech, Inc.

During the three months ended September 30, 2018, the Company completed its review of the amounts provisionally recorded as of December 31, 2017 related to the Tax Cuts and Jobs Act (the “Tax Act”). As a result of this review, there were no adjustments to the provisionally recorded amounts.